"People with moderate-to-severe atopic dermatitis cope with intense, sometimes unbearable symptoms that can impact them for most of their lives," said Julie Block, President and Chief Executive Officer, National Eczema Association. "To date, there have been few options available to treat people with moderate-to-severe atopic dermatitis who have uncontrolled disease. That's why today's approval of Dupixent is so important for our community. Now we have a treatment that is expected to help address patients suffering from this devastating disease."
Services Limited © 1997 - 2018
- Company Registration No. 03919014
Fully compliant with the Payment Card Industry Data Security Standard (PCI DSS). NCA Approved. Anti-Money Laundering Registration . Data Protection Reg No. Z3544745
MasterCard ® is a registered trademark of MasterCard International Inc. Visa ® is a registered trademark of Visa International Service Association.